Entero Healthcare Solutions
Market cap ₹8,652 Cr
- P/E
- 62.12
- Day range
- ₹1,935.80 – ₹2,018.10
- 52-week range
- ₹944.00 – ₹2,137.60
- Volume
- 82,992
- Open
- ₹1,979.90
- Prev close
- ₹1,966.60
Latest results · Q2 FY27(consolidated)Revenue ₹2,087 Cr+32.9%Profit ₹61 Cr+66.0%Margin 2.9%YoY vs the same quarter last year
1 red flag to read up on
- high
Under Additional surveillance (ASM)
The exchange has put this stock under Additional surveillance (ASM), Stage I · 18 Nov 2026
From NSE and BSE filings. A flag is a reason to read the filing, not a rating.
ENTERO in NSE indices and F&O
Research profile
Composite 57 / 100Factor percentiles
Derived metrics
- Earn. yield
- 1.6%
- Graham no.
- ₹551.91
- vs Graham
- -72.2%
- ROE ÷ P/B
- 1.8%
- 12-1 mom.
- +38.7%
- Return / vol
- 1.79
- Magic Formula
- #551
- Piotroski
- 3/6
- FCF yield
- 0.3%
- PEG
- 0.94
Appears in 14 scans
Percentiles rank this stock against the other tracked stocks and change as they do. Scans describe where figures sit today. Hover a label for its definition. Not investment advice.
Peer comparison
All 90 in Consumer| Company | M-cap | P/E | P/B | ROE | ROCE | OPM | D/E | Sales YoY |
|---|---|---|---|---|---|---|---|---|
| Titan CompanyTITAN | ₹4.12 L Cr | 58.67 | 23.83 | 37.1% | 21.0% | 14.0% | 1.51 | +10.1% |
| Asian PaintsASIANPAINT | ₹2.47 L Cr | 51.14 | 11.23 | 21.6% | 26.0% | 16.0% | 0.21 | +16.9% |
| Avenue SupermartsDMART | ₹2.26 L Cr | 72.59 | 8.60 | 12.9% | 17.0% | 7.0% | 0.16 | +17.8% |
| TrentTRENT | ₹1.70 L Cr | 89.73 | 21.75 | 27.7% | 28.0% | 18.0% | 0.30 | +21.9% |
| Lenskart SolutionsLENSKART | ₹1.27 L Cr | 162.33 | 13.71 | 6.8% | 8.0% | 22.0% | 0.37 | +35.7% |
| The Indian Hotels CompanyINDHOTEL | ₹1.25 L Cr | 56.35 | 9.29 | 18.6% | 17.0% | 28.0% | 0.25 | +21.7% |
| MeeshoMEESHO | ₹1.17 L Cr | 188.64 | 27.61 | -46.6% | -40.0% | -6.0% | 0.01 | +34.4% |
| Entero Healthcare SolutionsENTERO | ₹8,652 Cr | 62.12 | 4.81 | 8.6% | 10.0% | 5.0% | 0.51 | +32.8% |
| Sector median | ₹10,665 Cr | 40.83 | 4.83 | 13.0% | 15.0% | 12.5% | 0.27 | +19.1% |
Sector as classified in the tracked universe; medians use every tracked Consumer company, and P/E only profitable ones. Tinted figures beat the median.
Latest news
Updated 4h agoHeadlines about Entero Healthcare Solutions from the last two weeks in the financial press. Stories belong to their publishers; Rajat Finance does not endorse them.
Key metrics
- P/E (TTM)
- 60.5
- Price / Book
- 4.86
- ROE (FY26)
- 8.6%
- ROCE (latest year)
- 10%
- Dividend yield
- 0.00%
Moving averages (NSE)
- 20-day
- ₹1,734.35
- Price above
- 50-day
- ₹1,734.99
- Price above
- 200-day
- ₹1,349.33
- Price above
Charts & trends
From company filings. Amounts in ₹ crore.
Revenue, profit & margin - quarterly
₹ crore; a loss shows red. Operating margin below, same periods.
- Revenue
- Net profit
Operating margin
Who owns the company
% of equity by quarter, latest Sept 2026
- Promoter
- DII
- Public
- FII
Cash flows
Where cash came from and went, by fiscal year (₹ crore)
- Operating
- Investing
- Financing
- Free cash flow
Return on equity
Net profit over shareholders' equity, by fiscal year
Equity vs debt
Shareholders' equity against borrowings (₹ crore); the ratio below, same years.
- Equity
- Debt
Debt to equity
Financial statements
| Line item | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 993 | 1,034 | 1,097 | 1,301 | 1,359 | 1,339 | 1,404 | 1,571 | 1,707 | 1,910 | 1,940 | 2,087 |
| Expenses | 964 | 1,005 | 1,067 | 1,258 | 1,309 | 1,290 | 1,354 | 1,509 | 1,639 | 1,824 | 1,844 | 1,976 |
| Operating Profit | 29 | 29 | 30 | 42 | 50 | 49 | 50 | 62 | 68 | 86 | 97 | 111 |
| OPM % | 2.9% | 2.8% | 2.8% | 3.3% | 3.7% | 3.6% | 3.6% | 4% | 4% | 4.5% | 5% | 5% |
| Other Income | 2 | 9 | 13 | 11 | 8 | 7 | 6 | 5 | -4 | 4 | 3 | 4 |
| Interest | 16 | 17 | 10 | 11 | 10 | 10 | 11 | 12 | 14 | 17 | 21 | 23 |
| Depreciation | 6 | 7 | 7 | 7 | 8 | 8 | 9 | 10 | 10 | 15 | 12 | 13 |
| Profit before tax | 8 | 14 | 27 | 35 | 39 | 37 | 36 | 45 | 40 | 58 | 67 | 78 |
| Tax % | 16% | -56% | 25% | 25% | 25% | 16% | 17% | 18% | 16% | 22% | 22% | 23% |
| Net Profit | 7 | 21 | 21 | 26 | 29 | 31 | 30 | 37 | 34 | 45 | 52 | 61 |
| EPS in Rs | ₹1.91 | ₹4.82 | ₹4.62 | ₹5.43 | ₹5.85 | ₹5.90 | ₹6.39 | ₹7.26 | ₹6.35 | ₹6.44 | ₹8.77 | ₹10.46 |
From company filings, updated 19 Nov 2026. Consolidated figures where the company reports them. Information only, not investment advice.
Working-capital cycle
+17 days since Mar 2021
-2 days since Mar 2021
+23 days since Mar 2021
-8 days since Mar 2021
-19 days since Mar 2021
Strengths, risks & growth
Incorporated in 2018, Entero Healthcare Solutions Ltd is in the business of distribution and marketing of pharmaceutical and surgical products and allied services [1]
Strengths
- Company is expected to give good quarter
- Company has delivered good profit growth of 57.3% CAGR over last 5 years
- Company's working capital requirements have reduced from 49.4 days to 34.8 days
Risks
- Stock is trading at 4.85 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 6.04% over last 3 years.
Compounded Sales Growth
- 10 Years
- —
- 5 Years
- +30%
- 3 Years
- +26%
- TTM
- +35%
Compounded Profit Growth
- 10 Years
- —
- 5 Years
- +57%
- 3 Years
- +130%
- TTM
- +29%
Stock Price CAGR
- 10 Years
- —
- 5 Years
- —
- 3 Years
- —
- 1 Year
- +83%
Return on Equity
- 10 Years
- —
- 5 Years
- —
- 3 Years
- +6%
- Last Year
- +7%
Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.
Shareholding pattern
| Holder | Dec 2025 | Mar 2026 | Jun 2026 | Sept 2026 | Change |
|---|---|---|---|---|---|
| Promoter | 52.42% | 52.42% | 52.40% | 52.40% | 0.00 pp |
| FII | 5.14% | 4.03% | 4.36% | 5.76% | +1.40 pp |
| DII | 16.42% | 16.62% | 15.48% | 21.16% | +5.68 pp |
| Public | 26.03% | 26.94% | 27.77% | 20.67% | -7.10 pp |
Filed with NSE for Sept 2026: promoters 52.40%, public 47.60%
Analysts & fund holdings
Who holds the shares, quarter by quarter
Mutual funds 11.15% (+2.18 pp)- Promoters52.4%
- Foreign institutions5.8%
- Mutual funds11.2%
- Insurance0.0%
- Other domestic institutions10.0%
- Retail10.9%
- Others9.8%
| Fund | % of company | % of fund | 3-month change |
|---|---|---|---|
| Invesco India Contra Fund | 2.20% | 0.98% | +0.00 pp |
| HDFC Balanced Advantage Fund | 2.18% | 0.18% | +0.18 pp |
| Bank of India Flexi Cap Fund | 0.75% | 2.06% | +0.29 pp |
| ICICI Pru Healthcare Fund | 0.55% | 0.66% | -1.06 pp |
| Edelweiss Small Cap Fund | 0.52% | 0.66% | +0.66 pp |
Scorecard
- Performance
- Low
- Valuation
- High
- Growth
- Low
- Profitability
- Avg
- Entry point
- Good
- Red flags
- Avg
Analyst coverage, holdings and scorecard from market data; not a recommendation by Rajat Finance.
Risk & trend
From 292 daily sessions to 18 Nov 2026.
Risk
- Volatility (1Y)
- 41.2%
- Downside volatility
- 32.4%
- Worst 5% of days
- 3.4%
- Average of that tail
- 4.9%
- Max drawdown (1Y)
- 22.7%
- Below its peak
- 6.1%
Against the market
- Beta vs Nifty 50
- 0.42
- Correlation
- 0.14
- Relative strength (3M)
- +37.8%
- ATR (14)
- 4.6%
Return
- Return 1M
- +25.3%
- Return 3M
- +41.7%
- Return 6M
- +66.6%
- Return 1Y
- +73.8%
- vs 200-day average
- +47.2%
Momentum
- RSI (14)
- 67.4
- MACD histogram
- 32.59
- Stochastic %K
- 74.9
- ADX (14)
- 39.5
- +DI / −DI
- 34.0 / 10.3
- Money flow index
- 83.4
Participation
- Delivery (20d avg)
- 44.9%
- vs its 60-day baseline
- -3.8 pts
- Volume vs 20-day
- -0.5σ
- Close vs day's VWAP
- +0.7%
- 52-week position
- 89 / 100
These describe what this stock's price has already done. They are not forecasts, signals or recommendations, and a dash means the figure was withheld for want of enough history rather than being zero.
Financial quality
From consolidated statements to 30 Sept 2026.
Piotroski F-Score
3 of 6 tested
- Return on assets positive — passed
- Operating cash flow positive — not testableno cash flow statement for this period
- Return on assets improving — passed
- Cash flow exceeds profit — not testableneeds cash flow and profit against assets
- Debt to assets falling — failed
- Current ratio improving — failed
- No new equity issued — not testableno share count is collected, and financing cash flow mixes equity with debt
- Operating margin improving — passed
- Asset turnover improving — failed
- Free cash flow
- ₹29 Cr
- FCF yield
- 0.3%
- Cash conversion
- 0.66
- Accruals ratio
- 0.014
- Net debt
- ₹807 Cr
- Net debt / equity
- 0.45
- EV / sales
- 1.24
- PEG
- 0.94
- Capex intensity
- 1.0%
- Revenue CAGR
- 34.4%
- Profit CAGR
- 55.1%
Computed from filed statements, not filed themselves. A dash means an input was absent, and the score counts only the criteria that could actually be tested.
Corporate actions
Documents
Annual reports
Earnings calls
- Nov 2026Transcript
- Nov 2026TranscriptSlidesRecording
- Aug 2026TranscriptSlidesRecording
- Jun 2026TranscriptSlidesRecording
- Feb 2026TranscriptSlidesRecording
- Nov 2025TranscriptSlidesRecording
Credit ratings
- Rating update · 3 Dec 2025 from fitch
- Rating update · 9 Sep 2024 from fitch
- Rating update · 11 Feb 2021 from fitch
Documents open at BSE or the rating agency that issued them.
Sourced from the company's NSE XBRL filing dated 5 Nov 2026 (unaudited). View the source filing. Figures are as filed and are not investment advice.
Entero Healthcare Solutions: common questions
Answered from the figures on this page.